KCCure

A nonprofit raising research funding to cure #kidneycancer

[KCCure @kcCURE]

Honored to participate is this @KidneyCancer led effort bringing stakeholders together to answer a question that is crucial for #kidneycancer pts!

[Rana McKay, MD, FASCO @DrRanaMcKay]

Thank you Axel and Grant for organizing the INKCC moving towards developing a standardized neoadjuvant platform for RCC! ⁦@DrChoueiri⁩ ⁦@deepak_kilari⁩ ⁦@BradMcG04⁩ ⁦@myESMO⁩ #ESMO25

[KCCure @kcCURE]

Doctors! Tell us YOUR answer! How should the term “cure” be used in #kidneycancer? #ESMO25 Let’s see how many responses we can get! @DrChoueiri @montypal @DrYukselUrun @TiansterZhang @Uromigos @OncoAlert https://t.co/Ckxo46jcg7

[KCCure @kcCURE]

#KidneyCancer Patients want cures—but few believe they’re possible. Learn what patients living with metastatic RCC think about the word “cure." 📍Abstract 2636P | #ESMO25 #KidneyCancer #mRCC @TiansterZhang @spsutkaMD @DrVaishampayan @MichaelStaehler @lisapic @AlbigesL

[Toni Choueiri, MD @DrChoueiri]

Our @DanaFarber own Tony Letai to lead the @theNCI !

https://t.co/LKerspFl2f

[PeerView @PeerView]

Are you prepared to bring modern #RCC care to your patients across disease stages and histologic subtypes? Get guidance from Drs. Pal (@montypal), McDermott (@uromigos), & Zhang (@tiansterzhang). Produced with @KCCure. https://t.co/fwTMcoVyN9 #ASCO25 #MedEd

[Pavlos Msaouel @PavlosMsaouel]

1/5 This comes up in #kidneycancer clinic every few months. And on patient groups just as often.
📊 The ASSURE nomogram shows cumulative disease-free survival (DFS) from time 0 after surgery. Great info… until someone hits the 2-year mark and panics at that 48.8% 3-year number.

[PeerView @PeerView]

🎉 Just 2️⃣ days away!
Join PeerView for 15+ expert-led #CME symposia May 30–31 at #ASCO25!
🍽️ Dinner included
🎓 Free CME
🚌 McCormick shuttles to:
Gate 31 – Hyatt
Gate 26 – Hilton
Gate 21 – Sheraton
🔗 https://t.co/HtEL4wCzyE
❌ No ASCO reg needed for PeerView events only
@OncBrothers @jhaveri_komal @JavierCortesMD @Ahn_Daniel_Onc @SagarLonialMD @HansLeeMD1
@DrKrinaPatel @Ecastromarcos @JSabari @GlopesMd
@ZPiotrowskaMD @YJanjigianMD @ArndtVogel @HardingJJMD @MacarullaTeresa @NitinJainMD
@MCThompsonMD @KrishPatelMD @HTawbi_MD @TiansterZhang @montypal @CathyEngMD @GhayasIssa @HwakeleeMD @lipika_goyal
@AdamJSchoenfeld @BenCreelan
@JulieBrahmer @Daver_Leukemia @jaltmanmd

[KCCure @kcCURE]

📣 Live at #ASCO25: Learn from real-world #RCC cases with @montypal, Dr. McDermott & @TiansterZhang
 ✅ IO-based regimens
 ✅ Sequencing therapies
 ✅ Shared decision-making
 🗓️ May 31 | 7:00 PM CDT
 🔗 https://t.co/PNSrNPyw2J

[PeerView @PeerView]

Join Dr. Sumanta Kumar Pal (@montypal) & colleagues on Saturday, May 31, at 6:30 PM CDT/7:30 PM EDT during #ASCO25 for a #RenalCellCarcinoma #MedEd event. Produced with @KCCure. https://t.co/lJkRO9K17V #KidneyCancer #Oncology

[Daniel Shapiro @d_shapiro1]

His final presentation looking at barriers to genetic counseling in RCC. Congrats @PazLotan on an outstanding job at #AUA2025. @WiscUroOnc @wiscurology @ejasonabel @NakadaSteve

[Sumanta K. Pal, MD, FASCO @montypal]

I have been fielding a lot of calls from my #medonc colleagues around availability of #microbiome modulating studies for #kidneycancer at @cityofhope (in particular, #CBM588). The following are the two studies we have enrolling currently (limited slots remaining):

1. NCT06049576: Nivo/Ipi +/- camu camu (PI: @ReginaBarCar)
2. NCT06399419: Nivo/Ipi + CBM588 Dose Escalation/Expansion (PI: @arafflemd)

Investigators, please DM me with questions.

[Laura Esfeller @LauraEsfeller]

It’s my first #AUAAnnualMeeting - can you believe it?! Thanks @kcCURE for the invite! #AUA2025 #kidneycancer #patientadvocate

[Kimryn Rathmell @KimrynRathmell]

I’m honored to serve as the next CEO of the @osuccc_james & look forward to joining my new Buckeye colleagues at @osuwexmed & @ohiostate to take bold steps to advance the future of oncology across Ohio & nationally. Check out my LinkedIn to learn more. https://t.co/Mr1dw4eUXX

[Kidney Cancer @KidneyCancer]

🎉CONGRATULATIONS to @MichaelStaehler, recipient of the KCA's 2025 John Fitzpatrick Award recognizing excellence in urology care! The award will be presented at #IKCSEU25, don't miss his lecture! https://t.co/UAzsbVfCxE

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Glad to have this trial speed thru activation @utswcancer ! Enrollment is ongoing!

[Telix Pharmaceuticals @TelixPharma]

During her husband's five-year fight with kidney cancer, Dena Battle faced constant uncertainty.

The lack of accurate diagnostic tools made treatment decisions challenging, often providing conflicting results and leaving them in doubt.

Today, she is a dedicated patient advocate, working to provide surety to kidney cancer patients. Driven by her heartbreaking experience, she created @kcCURE to empower patients and support research focused on high-impact advancements in cancer care.

During Kidney Cancer Awareness Month, Telix is sitting down with physicians, advocates and patients to shed light on the current unmet needs in kidney cancer.

To learn more about Dena’s work visit: https://t.co/ATkt7frH58

U.S. patients and healthcare professionals can learn about how Telix is advancing kidney cancer detection and disease management at https://t.co/k9UgCOKvbp

For more on Telix’s portfolio visit: https://t.co/o80n5K9JU0

[Dena Battle @RCCadvocate]

70% of health-related internet searches are zero-click - which means pts are relying on snippets and AI overviews for information. When you see something like this that is outdated, misleading, or both - click on the feedback button. It's a small way you can help improve information for #kidneycancer patients.

[Daniel Heng @DrDanielHeng]

I really enjoyed this talk by @TiansterZhang #GU25 @ASCO. RCC is not Jupiter; it is so heterogenous. We try to refine prognostic criteria all the time and hopefully with molecular features or immune status or KIM1 we will succeed. @OncoAlert @DrChoueiri @IMDConline #sciencewins

[Katy Beckermann @katy_beckermann]

👀 Eye-opening data from @RCCadvocate & @kcCURE at #GU25:

�� 44% of #KidneyCancer patients spend hours thinking about cancer 🧠
🔹 36% visited the ER in the last 90 days 🚑
🔹 >1/3 say cancer always/often impacts eating, sleeping & social life 💔

Surviving is not the same as living. We must do better. #Oncology #PatientCare #RCC

[Sarah Scagliarini, MD @SScagliarini_]

@TiansterZhang @samsimsal @TurajlicLab 💡Adj therapy in #RCC
Outstanding presentation of @AlbigesL about:
Adjuvant for who?
How to discuss risk of relapse and risks associated with treatment
Identify the gaps & next steps in adjuvant setting

Oncologists’ Consensus & Patient perspective